Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI

Summary

This study is a prospective, randomized, open-label, single-center trial designed to compare the 30 month-safety and efficacy between low-dose (5mg/dL) and high-dose (20mg/dL) rosuvastatin treatment for patients with coronary artery disease after percutaneous coronary intervention with the newer drug-eluting stent.

Timeline

Start

2015-09

Primary completion

2019-06

Completion

2019-12

Drugs

Indications